Product
Ganitumab
Aliases
AMG 479, Anti-IGF-1R Human Monoclonal Antibody AMG-479
3 clinical trials
10 indications
Indication
Metastatic SarcomaIndication
SarcomaIndication
Resectable SarcomaIndication
Ewing SarcomaIndication
Ewing's SarcomaIndication
Bone MetastasisIndication
Bone Marrow MetastasisClinical trial
Pilot Trial of an Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With SarcomasStatus: Not yet recruiting, Estimated PCD: 2025-12-31
Clinical trial
Phase 2 Trial of Palbociclib and Ganitumab in Patients With Relapsed or Refractory Ewing SarcomaStatus: Completed, Estimated PCD: 2022-12-15
Clinical trial
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing SarcomaStatus: Active (not recruiting), Estimated PCD: 2021-03-31